Simone Rubant

700 total citations
21 papers, 520 citations indexed

About

Simone Rubant is a scholar working on Immunology, Dermatology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Simone Rubant has authored 21 papers receiving a total of 520 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Immunology, 11 papers in Dermatology and 3 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Simone Rubant's work include Psoriasis: Treatment and Pathogenesis (14 papers), Dermatology and Skin Diseases (11 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Simone Rubant is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (14 papers), Dermatology and Skin Diseases (11 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Simone Rubant collaborates with scholars based in Germany, United States and Canada. Simone Rubant's co-authors include Volker Specke, Joachim Denner, Wolf‐Henning Boehncke, Ralf J. Ludwig, Diamant Thaçi, Kim Papp, Josef Pfeilschifter, Roland Kaufmann, David Williams and Sandra Diehl and has published in prestigious journals such as Journal of Biological Chemistry, Frontiers in Immunology and Annals of the Rheumatic Diseases.

In The Last Decade

Simone Rubant

19 papers receiving 508 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Simone Rubant Germany	11	222	126	121	103	92	21	520
Christina Martins United States	12	406 1.8×	120 1.0×	52 0.4×	53 0.5×	113 1.2×	16	641
K.A. Lindstedt Finland	12	230 1.0×	38 0.3×	53 0.4×	45 0.4×	83 0.9×	22	462
Eva Hagforsen Sweden	17	493 2.2×	430 3.4×	88 0.7×	67 0.7×	113 1.2×	33	977
Chong Won Choi South Korea	14	162 0.7×	308 2.4×	45 0.4×	32 0.3×	169 1.8×	70	689
Katia Giuliodori Italy	17	283 1.3×	295 2.3×	92 0.8×	37 0.4×	96 1.0×	38	756
Tomoyasu Hattori Japan	11	74 0.3×	83 0.7×	65 0.5×	49 0.5×	231 2.5×	29	544
Takuwa Yasuda Japan	12	454 2.0×	56 0.4×	25 0.2×	41 0.4×	182 2.0×	18	849
David Piwnica France	12	83 0.4×	188 1.5×	36 0.3×	35 0.3×	190 2.1×	15	594
Hiroki Nakata Japan	14	64 0.3×	22 0.2×	74 0.6×	82 0.8×	209 2.3×	47	639
Stanca A. Birlea United States	16	360 1.6×	260 2.1×	22 0.2×	41 0.4×	202 2.2×	24	905

Countries citing papers authored by Simone Rubant

Since Specialization

Citations

This map shows the geographic impact of Simone Rubant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simone Rubant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simone Rubant more than expected).

Fields of papers citing papers by Simone Rubant

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simone Rubant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simone Rubant. The network helps show where Simone Rubant may publish in the future.

Co-authorship network of co-authors of Simone Rubant

This figure shows the co-authorship network connecting the top 25 collaborators of Simone Rubant. A scholar is included among the top collaborators of Simone Rubant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simone Rubant. Simone Rubant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Thaçi, Diamant, Mamitaro Ohtsuki, Julia‐Tatjana Maul, et al.. (2025). Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months. Dermatology and Therapy. 15(2). 381–394. 5 indexed citations

Papp, Kim, Mark Lebwohl, L. Puig, et al.. (2025). Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results. American Journal of Clinical Dermatology. 26(5). 829–841.

Warren, Richard B., et al.. (2024). 53999 Efficacy and safety after 52 weeks in psoriasis patients switching to risankizumab after suboptimal response to secukinumab or ixekizumab – a subgroup analysis. Journal of the American Academy of Dermatology. 91(3). AB35–AB35. 1 indexed citations

Hartmane, Ilona, et al.. (2024). Disease severity, treatment patterns, and quality of life in patients with moderate-to-severe psoriasis routinely managed with systemic treatment: results of the CRYSTAL observational study in Central and Eastern European countries. Frontiers in Immunology. 15. 1410540–1410540. 3 indexed citations

Warren, Richard B., Lev Pavlovsky, Antonio Costanzo, et al.. (2024). Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study. Dermatology and Therapy. 14(12). 3273–3290.

Crowley, Jeffrey, Chih-ho Hong, Melinda Gooderham, et al.. (2023). 44102 Risankizumab Efficacy for Moderate-to-Severe Plaque Psoriasis over 256 Weeks in Patients with Prior Biologic Treatments. Journal of the American Academy of Dermatology. 89(3). AB82–AB82. 1 indexed citations

Crowley, Jeffrey, Richard G. Langley, Kenneth B. Gordon, et al.. (2022). Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study. Dermatology and Therapy. 12(2). 561–575. 10 indexed citations

Strober, Bruce, et al.. (2022). Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders. Journal of Dermatological Treatment. 33(7). 2991–2996. 4 indexed citations

Thaçi, Diamant, Kilian Eyerich, Andreas Pinter, et al.. (2021). Direct comparison of risankizumab and fumaric acid esters in systemic therapy–naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial. British Journal of Dermatology. 186(1). 30–39. 15 indexed citations

10.

Thaçi, Diamant, Ahmed M. Soliman, Kilian Eyerich, et al.. (2021). Patient‐reported outcomes with risankizumab versus fumaric acid esters in systemic therapy‐naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial. Journal of the European Academy of Dermatology and Venereology. 35(8). 1686–1691. 19 indexed citations

11.

Papp, Kim, et al.. (2020). 14027 Long-term efficacy and safety of continuous q12w risankizumab: Results from the open-label extension LIMMitless trial. Journal of the American Academy of Dermatology. 83(6). AB17–AB17. 1 indexed citations

12.

Thaçi, Diamant, Kim Papp, Danielle Marcoux, et al.. (2019). Sustained long‐term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double‐blind, phase III study. British Journal of Dermatology. 181(6). 1177–1189. 25 indexed citations

13.

Menter, Alan, Diamant Thaçi, Kim Papp, et al.. (2015). Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis. Journal of the American Academy of Dermatology. 73(3). 410–419.e6. 42 indexed citations

14.

Mease, Philip J., Dafna D. Gladman, Christopher T. Ritchlin, et al.. (2015). AB0822 Therapeutic Response in Adalimumab-Treated Patients with Psoriatic Arthritis in Relation to Weight. Annals of the Rheumatic Diseases. 74. 1175–1175. 3 indexed citations

15.

Dudeck, Anne, et al.. (2010). Immature mast cells exhibit rolling and adhesion to endothelial cells and subsequent diapedesis triggered by E‐ and P‐selectin, VCAM‐1 and PECAM‐1. Experimental Dermatology. 19(5). 424–434. 31 indexed citations

16.

Essin, Kirill, Kerstin Hill, Heike A. Beschmann, et al.. (2008). Specific TRPC6 Channel Activation, a Novel Approach to Stimulate Keratinocyte Differentiation. Journal of Biological Chemistry. 283(49). 33942–33954. 88 indexed citations

17.

Rubant, Simone, Ralf J. Ludwig, Sandra Diehl, et al.. (2007). Dimethylfumarate Reduces Leukocyte Rolling in Vivo through Modulation of Adhesion Molecule Expression. Journal of Investigative Dermatology. 128(2). 326–331. 61 indexed citations

18.

Alban, Susanne, et al.. (2006). The influence of various structural parameters of semisynthetic sulfated polysaccharides on the P-selectin inhibitory capacity. Biochemical Pharmacology. 72(4). 474–485. 51 indexed citations

19.

Rubant, Simone, Ralf J. Ludwig, Roland Kaufmann, et al.. (2006). Eukaryotic expression of the broad‐spectrum chemokine receptor antagonist vMIP‐II and its effects on T‐cell function in vitro and in vivo. Experimental Dermatology. 15(8). 634–642. 10 indexed citations

20.

Specke, Volker, Simone Rubant, & Joachim Denner. (2001). Productive Infection of Human Primary Cells and Cell Lines with Porcine Endogenous Retroviruses. Virology. 285(2). 177–180. 113 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact